361342 Scalability and Impact of Freeze/Thaw Conditions on the Drug Substance Quality of Monoclonal Antibody Formulations

Thursday, November 20, 2014: 8:55 AM
203 (Hilton Atlanta)
William Rayfield1, Heera Khan2, Sunitha Kandula3, Matthew H. Flamm4 and Nihal Tugcu1, (1)Process Development and Engineering, Merck & Co., Inc., Kenilworth, NJ, (2)Merck, Kenilworth, NJ, (3)Protein Purification Development, Merck &Co, Union , NJ, (4)Merck, West Point, PA


Extended Abstract: File Not Uploaded